YOU ARE HERE:
Four more Ranbaxy drugs on WHO pre-qualification list
Ranbaxy Laboratories announced on 1st June that four more of its generic anti-HIV products have been included on the World Health Organization’s (WHO’s) list of prequalified medicines.
These four products - 600mg efavirenz tablets, 200mg efavirenz capsules, and 30 and 40mg d4T (stavudine) capsules - will now be available for organisations and countries in the developing world to buy at an affordable price.
Inclusion on the pre-qualification list means that the products are of good quality, safe and effective, and that their manufacturing sites comply with the WHO’s criteria.
Ranbaxy's chief executive officer and managing director, Malvinder Mohan Singh, said, “this is a significant development. We strongly feel that generic antiretrovirals are essential in the struggle against HIV / AIDS and are committed to providing high quality, cost-effective generics.”
Ranbaxy is an Indian company, which specialises in producing low-cost versions of drugs for sale in resource-limited countries. It now has twelve products on the pre-qualification list, as well as three antiretroviral products that have been approved by the United States Food and Drug Administration (FDA), making them eligible for purchase under the President's Emergency Plan for AIDS Relief (PEPFAR).
“Efavirenz is rapidly becoming a preferred drug in HIV treatment programmes in developing countries. The other newly listed drug, stavudine, is also being widely used as a first-line therapy against AIDS,” said Mr Singh. “Both products increase customer choice, enabling patients to access therapy easily, at affordable prices.”
The pre-qualification project was set up in 2001 by the WHO in collaboration with the Joint United Nations Programme on HIV / AIDS (UNAIDS), the United Nations Children's Fund (UNICEF), the United Nations Population Fund (UNFPA) and the World Bank. Its aim is to make the universal access to medicines easier by producing a list of medicines that meet standard levels of quality, safety and efficacy.
These four products - 600mg efavirenz tablets, 200mg efavirenz capsules, and 30 and 40mg d4T (stavudine) capsules - will now be available for organisations and countries in the developing world to buy at an affordable price.
Inclusion on the pre-qualification list means that the products are of good quality, safe and effective, and that their manufacturing sites comply with the WHO’s criteria.
Ranbaxy's chief executive officer and managing director, Malvinder Mohan Singh, said, “this is a significant development. We strongly feel that generic antiretrovirals are essential in the struggle against HIV / AIDS and are committed to providing high quality, cost-effective generics.”
Ranbaxy is an Indian company, which specialises in producing low-cost versions of drugs for sale in resource-limited countries. It now has twelve products on the pre-qualification list, as well as three antiretroviral products that have been approved by the United States Food and Drug Administration (FDA), making them eligible for purchase under the President's Emergency Plan for AIDS Relief (PEPFAR).
“Efavirenz is rapidly becoming a preferred drug in HIV treatment programmes in developing countries. The other newly listed drug, stavudine, is also being widely used as a first-line therapy against AIDS,” said Mr Singh. “Both products increase customer choice, enabling patients to access therapy easily, at affordable prices.”
The pre-qualification project was set up in 2001 by the WHO in collaboration with the Joint United Nations Programme on HIV / AIDS (UNAIDS), the United Nations Children's Fund (UNICEF), the United Nations Population Fund (UNFPA) and the World Bank. Its aim is to make the universal access to medicines easier by producing a list of medicines that meet standard levels of quality, safety and efficacy.
aidsmap resources
Africa news
- Africa: AIDS hits health services
- India legalises sex between men
- Scale up of early infant diagnosis in rural Ethiopia successful
Asia and Pacific news
- India legalises sex between men
- World Bank: Financial crisis threatens HIV treatment for 1.7 million
- Gates Foundation to fund trial of lower efavirenz dose
Eastern Europe and Russia news
- World Bank: Financial crisis threatens HIV treatment for 1.7 million
- HIV diagnoses in European MSM have almost doubled since 2000, UK tops the list
- Long hospital stays for TB treatment can increase risk of reinfection with MDR or XDR-TB strains
Latin America news
- Taking HIV treatment before conception increases risk of having a premature or low weight baby, Brazilian study shows
- CD4 cell count increases sustained up to five years in developing-world treatment programmes
- Brazil rejects tenofovir patent
Middle East news
- Justice Edwin Cameron calls for a campaign against 'misguided criminal laws and prosecutions'
- Half of all new HIV infections could be averted if proven prevention efforts expanded
- Roche agrees to temporary suspension of nelfinavir's (Viracept) European license - updated
Treatment access news
feedback
Give us your views on our work